Resultado de búsqueda
REBOOT is an NIH-funded weight loss trial being conducted at Rush University Medical Center. Scroll down to learn more . Click Here To See If You Qualify. The REBOOT Study was designed to find out why some people lose more weight in behavioral obesity treatment programs than others.
5 de may. de 2022 · The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF.
- Xavier Rossello, Sergio Raposeiras-Roubin, Roberto Latini, Alberto Dominguez-Rodriguez, José A Barra...
- 2021
What is REBOOT? REhabilitation after BOne marrOw Transplant to improve patient outcomes. Who is participating? Patients who are 18 years or over. Able to ambulate independently. 30 days after an autologous or allogeneic bone marrow transplant.
- Welcome to The Reboot Study
- About The Investigational Study Drug
- Reboot Part A
- Reboot Part B
The REBOOT study will test whether a combination of two different drugs, belimumab (Benlysta®) and rituximab (Rituxan®), is safe and if this combination is more effective at blocking the immune attack on the kidney in patients with Primary Membranous Neuropathy (MN) compared to rituximab alone.
Rituximab is a medication that works by blocking B cells (an immune cell that is known to have a role in autoimmune diseases like Primary MN). Rituximab is approved by the FDA for use in rheumatoid arthritis, vasculitis, and certain types of cancers. A few studies have shown that rituximab can be effective in treating some people with Primary MN, b...
People with Primary MN lose more protein in their urine because the filters in their kidneys may be damaged. It is possible that some belimumab may also be lost in the urine because of this. To make up for this loss, people with higher levels of protein in their urine may need a higher dose of belimumab than the FDA approved dose. One purpose of Pa...
Part B participants will be randomly assigned to 1 of 2 treatment groups. One group will receive weekly subcutaneous belimumab (self-injections under the skin) for 1 year. The other group will receive weekly subcutaneous belimumab placebo(an inactive substance that looks like the drug) for 1 year. All participants will receive intravenous (IV) ritu...
A clinical trial evaluating belimumab with rituximab for primary membranous nephropathy.
17 de oct. de 2023 · Esta app simplifica el reclutamiento de pacientes en el estudio y su aleatorización, así como la subida de documentos de los pacientes a partir de fotografías hechas desde tu dispositivo. También...
Abo S, Ritchie D, Denehy L et al. Feasibility of early-commencing group-based exercise in allogeneic bone marrow transplantation: the BOOST study. Bone Marrow Transplant. 2021;56:2788–2796. doi.org/10.1038/s41409-021-01411-w.
